Literature DB >> 17707829

Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells.

Nicholas Chiorazzi1.   

Abstract

Chronic lymphocytic leukemia (CLL) results from an accumulation of abnormal B cells due to an imbalance between birth and death rates such that the former exceeds the latter. This imbalance can occur as a result of increased birth, decreased death, or a combination of the two. CLL has long been considered a disease in which cell accumulation results from decreased death, due to a genetic defect, with minimal birth of the leukemic clone. This view was promulgated when experimental options were limited and observations in vivo and in vitro were less precise--e.g. CLL cells appeared as resting lymphocytes by light microscopy and responded poorly to mitogens (primarily T-cell mitogens)--at a time when T- and B-cell discrimination was not well appreciated. However, recent studies using more sophisticated measures suggest that the initial characterization of CLL biology needs re-evaluation. Using a safe, non-radioactive in-vivo labeling method that permits the determination of CLL-cell birth rates, we have directly documented that a small fraction of the clone (approximately 0.1-1.75%), i.e., between approximately 1x10(9) and 1x10(12) cells are born each day in all patients studied. With this value, we calculated death rates of between 0 and 1x10(12) per day of leukemic cells from individual patients. Thus the dynamic interplay between birth and death that characterizes other leukemias and lymphomas applies to CLL. Therefore, CLL is a disease of both proliferation and accumulation in which a homeostatic balance exists in patients with stable lymphocyte counts or an imbalance exists in patients with rising lymphocyte counts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707829     DOI: 10.1016/j.beha.2007.03.007

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  42 in total

Review 1.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

Review 2.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

3.  Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.

Authors:  Shih-Shih Chen; Rainer Claus; David M Lucas; Lianbo Yu; Jiang Qian; Amy S Ruppert; Derek A West; Katie E Williams; Amy J Johnson; Fred Sablitzky; Christoph Plass; John C Byrd
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

4.  Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton.

Authors:  Sandrine Barbier; Laurent Chatre; Marlène Bras; Patricia Sancho; Gaël Roué; Clémence Virely; Victor J Yuste; Sylvie Baudet; Manuel Rubio; Josep E Esquerda; Marika Sarfati; Hélène Merle-Béral; Santos A Susin
Journal:  Haematologica       Date:  2009-03-10       Impact factor: 9.941

5.  CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.

Authors:  A Efanov; N Zanesi; N Nazaryan; U Santanam; A Palamarchuk; C M Croce; Y Pekarsky
Journal:  Leukemia       Date:  2010-04-01       Impact factor: 11.528

Review 6.  miR deregulation in CLL.

Authors:  Veronica Balatti; Yuri Pekarky; Lara Rizzotto; Carlo M Croce
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

7.  Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.

Authors:  Urmila Santanam; Nicola Zanesi; Alexey Efanov; Stefan Costinean; Alexey Palamarchuk; John P Hagan; Stefano Volinia; Hansjuerg Alder; Laura Rassenti; Thomas Kipps; Carlo M Croce; Yuri Pekarsky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

8.  Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.

Authors:  Amit K Mittal; Nagendra K Chaturvedi; Karan J Rai; Christine E Gilling-Cutucache; Tara M Nordgren; Margaret Moragues; Runqing Lu; Rene Opavsky; Greg R Bociek; Dennis D Weisenburger; Javeed Iqbal; Shantaram S Joshi
Journal:  Mol Med       Date:  2014-07-15       Impact factor: 6.354

9.  Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression.

Authors:  Wei Ding; Grzegorz S Nowakowski; Traci R Knox; Justin C Boysen; Mary L Maas; Susan M Schwager; Wenting Wu; Linda E Wellik; Allan B Dietz; Asish K Ghosh; Charla R Secreto; Kay L Medina; Tait D Shanafelt; Clive S Zent; Timothy G Call; Neil E Kay
Journal:  Br J Haematol       Date:  2009-09-08       Impact factor: 6.998

10.  Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies.

Authors:  Gregory M Hayes; Robert Busch; Jason Voogt; Iche M Siah; Tracy A Gee; Marc K Hellerstein; Nicholas Chiorazzi; Kanti R Rai; Elizabeth J Murphy
Journal:  Leuk Res       Date:  2009-10-24       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.